Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
10
2020
accepted:
24
02
2021
entrez:
24
3
2021
pubmed:
25
3
2021
medline:
22
4
2021
Statut:
epublish
Résumé
Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed. We hypothesized that colchicine, by counteracting proinflammatory pathways implicated in the uncontrolled inflammatory response of COVID-19 patients, reduces pulmonary complications, and improves survival. This retrospective study included 71 consecutive COVID-19 patients (hospitalized with pneumonia on CT scan or outpatients) who received colchicine and compared with 70 control patients who did not receive colchicine in two serial time periods at the same institution. We used inverse probability of treatment propensity-score weighting to examine differences in mortality, clinical improvement (using a 7-point ordinary scale), and inflammatory markers between the two groups. Amongst the 141 COVID-19 patients (118 [83.7%] hospitalized), 70 (50%) received colchicine. The 21-day crude cumulative mortality was 7.5% in the colchicine group and 28.5% in the control group (P = 0.006; adjusted hazard ratio: 0.24 [95%CI: 0.09 to 0.67]); 21-day clinical improvement occurred in 40.0% of the patients on colchicine and in 26.6% of control patients (adjusted relative improvement rate: 1.80 [95%CI: 1.00 to 3.22]). The strong association between the use of colchicine and reduced mortality was further supported by the diverging linear trends of percent daily change in lymphocyte count (P = 0.018), neutrophil-to-lymphocyte ratio (P = 0.003), and in C-reactive protein levels (P = 0.009). Colchicine was stopped because of transient side effects (diarrhea or skin rashes) in 7% of patients. In this retrospective cohort study colchicine was associated with reduced mortality and accelerated recovery in COVID-19 patients. This support the rationale for current larger randomized controlled trials testing the safety/efficacy profile of colchicine in COVID-19 patients.
Identifiants
pubmed: 33760858
doi: 10.1371/journal.pone.0248276
pii: PONE-D-20-29570
pmc: PMC7990208
doi:
Substances chimiques
Colchicine
SML2Y3J35T
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0248276Subventions
Organisme : NIAID NIH HHS
ID : U01 AI063594
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Reumatol Clin (Engl Ed). 2021 Aug-Sep;17(7):371-375
pubmed: 34301378
Medicine (Baltimore). 2020 Apr;99(16):e19814
pubmed: 32312000
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Clin Immunol. 2020 Aug;217:108490
pubmed: 32492478
Curr Pharm Des. 2018;24(6):654-658
pubmed: 29336251
J Infect Public Health. 2020 Apr;13(4):644-646
pubmed: 32199792
N Engl J Med. 2013 Oct 17;369(16):1522-8
pubmed: 23992557
PLoS One. 2020 Dec 2;15(12):e0242318
pubmed: 33264297
Clin Ther. 2019 Jan;41(1):41-48
pubmed: 30591286
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Ann Rheum Dis. 2020 Oct;79(10):1286-1289
pubmed: 32732245
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Am Heart Assoc. 2015 Aug 24;4(8):e002128
pubmed: 26304941
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Pediatrics. 2019 May;143(5):
pubmed: 31000685
Virology. 2015 Nov;485:330-9
pubmed: 26331680
JAMA Netw Open. 2020 Jun 1;3(6):e2013136
pubmed: 32579195
mBio. 2018 May 22;9(3):
pubmed: 29789363